- Price
- $306.28
- Day
- -0.68%
- Mkt Cap
- $59.59B
- 52W Range
- $244.82 – $377.54
- Volume
- 1.65M
- Beta
- 0.57
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Company Advances Strategic Pharmacy Relationships, Expands Commercial Pipeline and Positions for Continued Growth Across the Healthcare Marketplace JACKSON, WY / ACCESS Newswire / August 3, 2026 / Kultura Brands, Inc. (OTCID:LTNC) today announced the successful completion of its participation at Cencora ThoughtSpot 2026, where the Company strengthened strategic relationships, expanded its commercial pipeline and advanced multiple initiatives designed to support the continued growth of its healthcare platform. ThoughtSpot is one of the independent pharmacy industry's premier annual events, bringing together pharmacy owners, healthcare professionals, manufacturers, suppliers and industry leaders from across the country.
Read full article
COR's Q3 results could reflect specialty pharma strength, oncology expansion and margin gains, even as pricing dynamics and GLP-1 trends pressure revenues.
Read full article
BankChampaign National Association acquired a new stake in Cencora, Inc. (NYSE: COR) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,060 shares of the company's stock, valued at approximately $647,000. Several other hedge funds have also recently added to or reduced
Read full article
Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Read full article
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Delta Global Management LP bought a new stake in shares of Cencora, Inc. (NYSE: COR) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,567 shares of the company's stock, valued at approximately $1,435,000. Several other hedge funds have also made changes to
Read full article
Bank of Nova Scotia grew its stake in shares of Cencora, Inc. (NYSE: COR) by 7.7% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 186,015 shares of the company's stock after acquiring an additional 13,366 shares during
Read full article
COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.
Read full article
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Read full article
Cencora (COR) is transitioning from a bulk pharmaceutical distributor to a specialty medicines infrastructure provider, targeting higher-margin, service-driven growth. Recent acquisitions of OneOncology and Retina Consultants of America are driving margin expansion, with Q2 adjusted gross profit up 15.7% and margin rising to 4.31%. Management raised FY2026 adjusted EPS guidance to $17.70–$17.90, expects $3B adjusted FCF, and targets 10–14% long-term EPS growth.
Read full article
On July 16, 2026, Cencora Inc (COR) shares rose 3.9% to a current price of $307.99. This price performance is notable as it sits within a 52-week range of $244.
Read full article
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.
Read full article